AprepitantAprepitant is a specific NK-1R antagonist, used as an antiemetic agent. CAS# 170729-80-3 |
- Biapenem
Catalog No.:BCC1071
CAS No.:120410-24-4
- (S)-Tedizolid
Catalog No.:BCC1294
CAS No.:1431699-67-0
- Tulathromycin A
Catalog No.:BCC2019
CAS No.:217500-96-4
- Doripenem Hydrate
Catalog No.:BCC1160
CAS No.:364622-82-2
- Toltrazuril sulfone
Catalog No.:BCC2008
CAS No.:69004-04-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 170729-80-3 | SDF | Download SDF |
| PubChem ID | 151165 | Appearance | Powder |
| Formula | C23H21F7N4O3 | M.Wt | 534.43 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Emend; MK-869; MK-0869; Aprepitantum | ||
| Solubility | DMSO : ≥ 100 mg/mL (187.12 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one | ||
| SMILES | CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NC(=O)NN3)C4=CC=C(C=C4)F | ||
| Standard InChIKey | ATALOFNDEOCMKK-BYYRLHKVSA-N | ||
| Standard InChI | InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19-,20+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Aprepitant decreases the metabolic activity with an estimated IC50 value of 20 µM. Aprepitant induces cell-growth inhibition and G1 cell-cycle arrest. Aprepitant significantly induces apoptosis in Nalm-6 cells, and the apoptosis is mediated through caspase-3 activation. Aprepitant (20 µM) induces p53 accumulation and expression of pro-apoptotic p53 target genes. Aprepitant (1, 5, 10 µM) inhibits HIV infection in MDM from both depressed and not depressed HIV negative individuals ex vivo in a dose-dependent manner. IC90 value of aprepitant is equivalent to 10 μM, and the IC50 value is about 5 μM. Aprepitant prevents the increase of NK-1R expression induced by in vivo NHP infection with B. burgdorferi. Aprepitant treatment prevents B. burgdorferi-induced increases in CCL2 protein levels in the CSF of NHPs. Aprepitant treatment prevents B. burgdorferi-induced increases in CCL2 and CXCL13 mRNA expression in the dorsal root ganglia of NHPs, prevents B. burgdorferi-induced increases in CCL2, CXCL13, IL-17A, and IL-6 mRNA expression in the spinal cord of NHPs. Aprepitant treatment attenuates B. burgdorferi infection-induced reductions in astrocyte activity/numbers. Aprepitant (10 mg/kg, i.p.) significantly attenuates the CPP expression and locomotor activation produced by AMPH and cocaine in mice. In contrast, aprepitant significantly enhances the expression of CPP produced by morphine while significantly suppressing the locomotor activity of the mice conditioned with morphine. Aprepitant does not induce significant CPP or conditioned place aversion or locomotor activation or suppression. Aprepitant (125 mg/day, p.o.) results in 1 log reduction in plasma levels of viral RNA as compared to non-treated controls. | |||||
Aprepitant Dilution Calculator
Aprepitant Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8712 mL | 9.3558 mL | 18.7115 mL | 37.423 mL | 46.7788 mL |
| 5 mM | 0.3742 mL | 1.8712 mL | 3.7423 mL | 7.4846 mL | 9.3558 mL |
| 10 mM | 0.1871 mL | 0.9356 mL | 1.8712 mL | 3.7423 mL | 4.6779 mL |
| 50 mM | 0.0374 mL | 0.1871 mL | 0.3742 mL | 0.7485 mL | 0.9356 mL |
| 100 mM | 0.0187 mL | 0.0936 mL | 0.1871 mL | 0.3742 mL | 0.4678 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Aprepitant (also known as MK-0869) is a novel and highly selective Neurokinin-1 (NK-1) receptors that inhibits the activity of substance P (SP), an undecapeptide belonging to the tachykinin family of peptides, on the NK-1 receptor with the dissociation constant Kd of 86 pM for human NK-1 receptor and the half maximal inhibition concentration IC50 of 0.1 nM, 4 nM and 0.7 nM for human, rat and ferret NK-1 receptors respectively [1,2].
Since SP has been demonstrated to induce cell proliferation in several human cancer cell lines with overexpressed NK-1 receptors, aprepitant has also been found to concentration-dependently induce growth inhibition in a variety of tumor cell lines, including glioma (GAMG), neuroblastoma (SKN-BE2, IMR-32 and KELLY), retinoblastoma (Y-79 and WERI-Rb-1), pancreas carcinoma (PA-TU-8902 and CAPAN-1), larynx carcinoma (HEp-2), gastric carcinoma (23132-87) and colon carcinoma (SW-403), with IC50 of 33.1 μΜ, 24.6 μΜ, 19.6 μΜ, 27.7 μΜ, 30.4 μΜ, 23 μΜ, 31.2 μΜ, 27.4 μΜ, 22.7 μΜ, 24.2 μΜ and 30.5 μΜ respectively [2].
References:
[1] Tattersall FD1, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000 Feb 14;39(4):652-63.
[2] Muñoz M1, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs. 2010 Apr;28(2):187-93. doi: 10.1007/s10637-009-9218-8. Epub 2009 Jan 17.
- 11-Deoxymogroside V
Catalog No.:BCN8143
CAS No.:1707161-17-8
- Nociceptin
Catalog No.:BCC5686
CAS No.:170713-75-4
- 6beta-Hydroxyhispanone
Catalog No.:BCN7453
CAS No.:170711-93-0
- Bindone
Catalog No.:BCC8877
CAS No.:1707-95-5
- D-Mannitol diacetonide
Catalog No.:BCC8951
CAS No.:1707-77-3
- α-Conotoxin EI
Catalog No.:BCC5979
CAS No.:170663-33-9
- Fmoc-D-Abu-OH
Catalog No.:BCC3203
CAS No.:170642-27-0
- YC 1
Catalog No.:BCC7912
CAS No.:170632-47-0
- Oteromycin
Catalog No.:BCN1849
CAS No.:170591-45-4
- SC 236
Catalog No.:BCC7809
CAS No.:170569-86-5
- Isohyperectine
Catalog No.:BCN3405
CAS No.:170384-75-5
- 1,4-Epidioxybisabola-2,10-dien-9-one
Catalog No.:BCN7532
CAS No.:170380-69-5
- Trityl candesartan cilexetil
Catalog No.:BCC9188
CAS No.:170791-09-0
- Astressin
Catalog No.:BCC5790
CAS No.:170809-51-5
- CHPG
Catalog No.:BCC6910
CAS No.:170846-74-9
- E4CPG
Catalog No.:BCC6888
CAS No.:170846-89-6
- (RS)-APICA
Catalog No.:BCC6925
CAS No.:170847-18-4
- PNU 96415E
Catalog No.:BCC7467
CAS No.:170856-41-4
- Sonepiprazole
Catalog No.:BCC7879
CAS No.:170858-33-0
- Cyasterone
Catalog No.:BCN5416
CAS No.:17086-76-9
- Persianone
Catalog No.:BCN7359
CAS No.:170894-20-9
- Aburatubolactam A
Catalog No.:BCN1821
CAS No.:170894-24-3
- Donitriptan hydrochloride
Catalog No.:BCC7742
CAS No.:170911-68-9
- Dihydroactinidiolide
Catalog No.:BCN6890
CAS No.:17092-92-1
Production of aprepitant nanocrystals by wet media milling and subsequent solidification.[Pubmed:28257885]
Int J Pharm. 2017 Nov 30;533(2):324-334.
The present study investigates the effects of formulation and process parameters on the production of Aprepitant nanosuspensions applying wet media milling and subsequent solidification. Six stabilizers were used: two brands of hydroxylpropylmethyl cellulose (HPMC E-15LV and Pharmacoat 603), hydroxypropyl cellulose (HPC-SSL), polyvinylpyrollidone (PVP), D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS 1000), Poloxamer P188 and sodium dodecyl sulfate (SDS), while two diluents (mannitol and sucrose) were incorporated prior to solidification by two methods (spray- and freeze-drying). The polymorphic purity of the raw material, the particle size of nanocrystals, and the physicochemical properties of the final dried powders were assessed. Focus was placed on the energetic aspects of the crystal structure of Aprepitant in order to rationalize particle breakage during wet milling. It was found that a combination of cellulosic polymers with SDS are suitable stabilizers for the production of Aprepitant nanocrystals ( approximately 300nm or smaller) by wet media milling. Regarding the solidification of the nanosuspensions, spray-drying is advantageous compared to freeze-drying, as it leads to the production of almost spherical individual micron-sized agglomerates of nanocrystals and few secondary agglomerates of them which are expected to exhibit improved handling behavior. Spray-dried nanocrystal agglomerates containing Pharmacoat 603 and mannitol exhibit reduced hygroscopity compared to those prepared with sucrose and HPC-SSL, making them the excipients of choice.
Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.[Pubmed:28302100]
BMC Cancer. 2017 Mar 16;17(1):200.
BACKGROUND: Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. CASE PRESENTATIONS: We report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days) following Aprepitant treatment. CONCLUSION: Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent Aprepitant administration. These cases further demonstrate that Aprepitant can be considered as a therapeutic option in malignancy-associated pruritus and further support the need for larger clinical trials.
Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.[Pubmed:28198358]
Med Sci Monit. 2017 Feb 15;23:826-833.
BACKGROUND The aim of this study was to evaluate the antiemetic effect of Aprepitant and to determine how to provide triple combination therapy (Aprepitant/azasetron/dexamethasone) to women receiving paclitaxel/carboplatin moderately emetogenic chemotherapy (MEC). MATERIAL AND METHODS The current study was a prospective study of 163 women with gynecologic cancers. We compared the digestive symptoms scores (nausea, vomiting, appetite loss, and dietary intake) of 37 women with ovarian cancers before and after Aprepitant administration. We also compared these symptoms in women who underwent 193 cycles of triple combination therapy with symptoms of women who underwent 226 cycles of double combination therapy. For triple combination therapy, azasetron, dexamethasone (reduced dose: 40% of 20 mg), and Aprepitant (125 mg) were administered on Day 1, followed by only Aprepitant (80 mg) administration on Days 2 and Day 3. RESULTS In 37 women with ovarian cancer, three symptoms, nausea, appetite loss, and dietary intake, were significantly improved by primarily adding Aprepitant to double combination therapy in the delayed phase of MEC. Upon comparing their digestive symptoms in all cycles, however, these three symptoms were not significantly different in the delayed phase. Furthermore, all four symptoms in all cycles were worse following triple combination therapy than following double combination therapy in the acute phase (p<0.02). The control of digestive symptoms was generally insufficient without the administration of dexamethasone. CONCLUSIONS Primary Aprepitant as an addition to MEC demonstrated efficacy in improving digestive symptoms in the delayed phase. However, its effect may decrease with repeated use. To improve the antiemetic effect, the dose reduction of dexamethasone should be restricted on Day 1 and dexamethasone should be used throughout the delayed phase as well.
Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis.[Pubmed:28202084]
J Neuroinflammation. 2017 Feb 15;14(1):37.
BACKGROUND: Substance P (SP) is produced at high levels in the central nervous system (CNS), and its target receptor, neurokinin 1 receptor (NK-1R), is expressed by glia and leukocytes. This tachykinin functions to exacerbate inflammatory responses at peripheral sites. Moreover, SP/NK-1R interactions have recently been associated with severe neuroinflammation and neuronal damage. We have previously demonstrated that NK-1R antagonists can limit neuroinflammatory damage in a mouse model of bacterial meningitis. Furthermore, we have since shown that these agents can attenuate Borrelia burgdorferi-induced neuronal and glial inflammatory mediator production in non-human primate brain explants and isolated neuronal cells. METHODS: In the present study, we have assessed the role played by endogenous SP/NK-1R interactions in damaging CNS inflammation in an established rhesus macaque model that faithfully reproduces the key clinical features of Lyme neuroborreliosis, using the specific NK-1R antagonist, Aprepitant. We have utilized multiplex ELISA to quantify immune mediator levels in cerebrospinal fluid, and RT-PCR and immunoblot analyses to quantify cytokine and NK-1R expression, respectively, in brain cortex, dorsal root ganglia, and spinal cord tissues. In addition, we have assessed astrocyte number/activation status in brain cortical tissue by immunofluorescence staining and confocal microscopy. RESULTS: We demonstrate that Aprepitant treatment attenuates B. burgdorferi-induced elevations in CCL2, CXCL13, IL-17A, and IL-6 gene expression in dorsal root ganglia, spinal cord, and/or cerebrospinal fluid of rhesus macaques at 2 to 4 weeks following intrathecal infection. In addition, we demonstrate that this selective NK-1R antagonist also prevents increases in total cortical brain NK-1R expression and decreases in the expression of the astrocyte marker, glial fibrillary acidic protein, associated with B. burgdorferi infection. CONCLUSIONS: The ability of a centrally acting NK-1R inhibitor to attenuate B. burgdorferi-associated neuroinflammatory responses and sequelae raises the intriguing possibility that such FDA-approved agents could be repurposed for use as an adjunctive therapy for the treatment of bacterial CNS infections.
